StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) company profile

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.16−0.04 (-1.82%)

Close on Nov 17, 2026Market cap $103.14MP/E –Yield –

About Minerva Neurosciences

Pharmaceutical Preparations, SIC 2834

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary product candidates for individuals suffering from central nervous system disorders. The company’s principal development pipeline centers on roluperidone, an investigational therapy designed to target negative symptoms in patients diagnosed with schizophrenia. As a development-stage biopharmaceutical organization, its prospective customer base encompasses healthcare providers, medical facilities, and the broader patient population requiring treatment for central nervous system indications.

The company operates as a single reporting segment without commercial product sales, commercial distribution channels, or dedicated marketing and sales infrastructure. In terms of geographical presence, its clinical development programs involve patient recruitment across clinical trial sites situated in the United States and international locations. Minerva Neurosciences maintains its corporate headquarters and principal executive offices in Burlington, Massachusetts.

Summary of the business section of Minerva Neurosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Minerva Neurosciences, Inc.
Founded
2007
Headquarters
Burlington, MA
Address
1500 District Avenue 01803
Phone
(617) 600-7373
Employees
7, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Massachusetts
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
NERV
Exchange
Nasdaq
IPO date
Jul 1, 2014
Shares outstanding
48M, Aug 4, 2026
Public float
$7.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-8 reverse, Jun 21, 2022
SEC CIK
1598646
CUSIP
603380205
ISIN
US6033802058
FIGI
BBG0067S9Z73
Share class FIGI
BBG0067S9Z82
LEI
54930017PANCHC5LYH79
EIN
26-0784194

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Remy LuthringerCEO, Director184,819
Anthony AliquoChief Accounting Officer1,683
Joseph H. ReillyChief Operating Officer20,872
Frederick W. AhlholmSVP, CFO and Secretary17,518
James Joseph O'ConnorChief Business Officer and GC–
Geoff RacePresident51,324
Inderjit KaulDirector–
David KupferDirector191,488
Hans Peter HaslerDirector10,000
Heek G. Jan VanDirector20,333
Fouzia Laghrissi-ThodeDirector0

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$9.35M$9.86M$4.38M$253–
FY2024$1.21M$1.26M$836.94K$140–
FY2023$1.84M$2.13M$1.18M$387–
FY2022$1.27M$1.28M$791.90K$25–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Remy Luthringer
Chief Executive Officer
$675.03K$482.64K$8.19M$6.51K$9.35M+673%
Geoffrey Race
Former President
$511.70K$307.02K$5.46M$3.33K$6.28M+583%
Frederick Ahlholm
Chief Financial Officer
$467.49K$168.30K$1.82M$13.42K$2.47M+227%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 1, 2014
Offer price
$6.00
Securities offered
5,454,545
Gross proceeds
$32.73M
Exchange
Nasdaq
First trading day
Jul 1, 2014
First-day close
$6.05+0.8%
Lock-up ends (est.)
Dec 28, 2014

“The initial public offering price is $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 7 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?